Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Replication incompetent human adenovirus serotype 5 has been extensively used as a delivery vehicle for gene therapy proteins and infectious disease antigens. These vectors infect replicating and non-replicating cells, have a broad tissue tropism, elicit high immune responses and are easily purified to high titres. However, the utility of HAdV-C5 vectors as potential vaccines is limited due to pre-existing immunity within the human population which significantly reduces the immunogenicity of HAdV-C5 vaccines. In recent years, adenovirus vaccine development has focused on simian-derived adenoviral vectors which have the desirable vector characteristics of HAdV-C5 but with negligible seroprevalence in the human population. Here, we discuss recent advances in simian adenovirus vaccine vector development and evaluate current research specifically focusing on clinical trial data.

Original publication

DOI

10.2217/fvl-2016-0070

Type

Journal article

Journal

Future Virology

Publisher

Future Medicine

Publication Date

15/09/2016

Volume

11

Pages

649 - 659

Keywords

vector vaccine, Chimpanzee adenoviruses, clinical trails , Simian adenoviruses, BAC recombineering